A six-monthly abdominal ultrasound, in combination with alpha fetoprotein (AFP) measurement, is recommended as a screening method for at-risk groups or target populations, including those with liver cirrhosis, by the European Association for the Study of the Liver and the American Association for the Study of Liver Diseases (8, 9). Here, AFP is linked to liver disorder.